| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 38
| Issue : 2 | Page : 99-109 |
|
|
Potential of nuclear magnetic resonance metabolomics in the study of prostate cancer
R Ravikanth Reddy1, Naranamangalam R Jagannathan2
1 Department of Radiology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, India
2 Department of Radiology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam; Department of Radiology, Sri Ramachandra Institute of Higher Education and Research; Department of Electrical Engineering, Indian Institute Technology Madras, Chennai, Tamil Nadu, India
Correspondence Address:
Naranamangalam R Jagannathan
Department of Radiology, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam; Department of Radiology, Sri Ramachandra Institute of Higher Education and Research; Department of Electrical Engineering, Indian Institute Technology Madras, Chennai, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/iju.iju_416_21
|
|
|
Nuclear magnetic resonance (NMR) metabolomics is a powerful analytical technique and a tool which has unique characteristics and capabilities for the evaluation of a number of biochemicals/metabolites of cancer and other disease processes that are present in biofluids (urine and blood) and tissues. The potential of NMR metabolomics in prostate cancer (PCa) has been explored by researchers and its usefulness has been documented. A large number of metabolites such as citrate, choline, and sarcosine were detected by NMR metabolomics from biofluids and tissues related to PCa and their levels were compared with controls and benign prostatic hyperplasia. The changes in the levels of these metabolites aid in the diagnosis and help to understand the dysregulated metabolic pathways in PCa. We review recent studies on in vitro and ex vivo NMR spectroscopy-based PCa metabolomics and its possible role as a diagnostic tool. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
